Major Estimate Revision • Apr 29
Consensus revenue estimates increase by 20% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from UK£10.3m to UK£12.4m. EPS estimate increased from UK£0.03 to UK£0.034 per share. Net income forecast to grow 1,585% next year vs 35% growth forecast for Chemicals industry in the United Kingdom. Consensus price target up from UK£0.45 to UK£0.52. Share price rose 11% to UK£0.36 over the past week. Bekanntmachung • Apr 28
Hardide plc to Report First Half, 2026 Results on May 21, 2026 Hardide plc announced that they will report first half, 2026 results on May 21, 2026 Bekanntmachung • Mar 05
Hardide plc, Annual General Meeting, Mar 24, 2026 Hardide plc, Annual General Meeting, Mar 24, 2026. Location: 9 longlands road, bicester, oxfordshire ox26 5ah, United Kingdom Reported Earnings • Mar 02
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: UK£0.002 (up from UK£0.019 loss in FY 2024). Revenue: UK£6.03m (up 28% from FY 2024). Net income: UK£178.0k (up UK£1.50m from FY 2024). Profit margin: 3.0% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.3%. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Feb 27
Consensus revenue estimates increase by 14% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from UK£9.00m to UK£10.3m. EPS estimate increased from UK£0.019 to UK£0.03 per share. Net income forecast to grow 1,248% next year vs 29% growth forecast for Chemicals industry in the United Kingdom. Consensus price target up from UK£0.30 to UK£0.45. Share price rose 46% to UK£0.38 over the past week. Major Estimate Revision • Feb 04
Consensus revenue estimates increase by 13% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from UK£8.00m to UK£9.00m. EPS estimate increased from UK£0.015 to UK£0.019 per share. Net income forecast to grow 743% next year vs 31% growth forecast for Chemicals industry in the United Kingdom. Consensus price target of UK£0.30 unchanged from last update. Share price rose 44% to UK£0.24 over the past week. Reported Earnings • Jan 23
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: UK£0.002 (up from UK£0.019 loss in FY 2024). Revenue: UK£6.03m (up 28% from FY 2024). Net income: UK£178.0k (up UK£1.50m from FY 2024). Profit margin: 3.0% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.3%. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. New Risk • Dec 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (UK£10.8m market cap, or US$14.4m). New Risk • Dec 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Market cap is less than US$100m (UK£7.98m market cap, or US$10.6m). Bekanntmachung • Mar 19
Hardide plc Provides Earning Guidance for the First Half Year Ending 31 March, 2025 Hardide plc provided earning guidance for the first half year ending 31 March, 2025. For the period, The company expects revenues for the first half year ending 31 March 2025 ("H1 FY25") to be approximately 30% ahead of the £2.1 million reported in the equivalent prior year period ("H1 FY24"). Bekanntmachung • Mar 03
Hardide plc, Annual General Meeting, Mar 18, 2025 Hardide plc, Annual General Meeting, Mar 18, 2025. Location: hardide plc, 9 longlands road, bicester, oxfordshire ox26 5ah, United Kingdom New Risk • Feb 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Market cap is less than US$10m (UK£5.57m market cap, or US$6.98m). Minor Risk Currently unprofitable and not forecast to become profitable next year (UK£100k net loss next year). Reported Earnings • Jan 30
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: UK£0.019 loss per share (in line with FY 2023). Revenue: UK£4.73m (down 14% from FY 2023). Net loss: UK£1.32m (loss widened 18% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 12%. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Market cap is less than US$10m (UK£4.32m market cap, or US$5.27m). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£702k net loss next year). Share price has been volatile over the past 3 months (9.9% average weekly change). New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£4.81m market cap, or US$6.10m). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£702k net loss next year). Share price has been volatile over the past 3 months (9.6% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). New Risk • Dec 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£3.92m market cap, or US$5.00m). Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£702k net loss next year). Shareholders have been diluted in the past year (33% increase in shares outstanding). Bekanntmachung • Dec 03
Hardide plc Announces Board and Committee Changes Hardide plc announced the appointment of Dr. Bryan Allcock to the Board on 3 December 2024 as an Independent Non-Executive Director. Bryan will succeed Tim Rice as Hardide's Senior Independent Director and Chair of the Remuneration Committee with effect from 1 January 2025, as Tim will be stepping down from the Board on 31 December 2024. Bryan has career long experience working in the advanced materials, surface engineering and coatings industry. He is currently CEO of his own business, TRL9 Limited, which runs a portfolio of research, development and deployment projects, including the use of high entropy alloys. Bryan acts as a subject matter expert to the Ministry of Defence and BAE Systems for the coating of flight decks for Queen Elizabeth Class aircraft carriers and has collaborative research contracts with Jaguar Land Rover, the Defence and Security Accelerator (DASA) and the European Space Agency. Bryan was formerly Global CEO for the Services business of Castolin Eutectic Limited, part of the Messer Group, where he ran an international £56 million revenue business delivering surface engineering and advanced coating solutions. Bryan joined Castolin Eutectic having sold his own business, Monitor Coatings, to them in 2013. Bryan spent his earlier career as Head of Technical Services at Flight Refuelling Limited, part of Cobham plc, where he grew profits significantly through business development of the coatings division, operational improvement and efficiency initiatives. Bryan holds an MBA, has a degree in applied chemistry and materials, and holds a PhD in Corrosion Engineering from Cranfield University. He is a fellow of the Institute of Materials, Minerals and Mining and has been a strategic advisor to the Institute. Dr. Bryan Allcock BSc (Hons) PhD, MBA, FIMMM (Age 57). Current Directorships: TRL9 Limited, Solar Fluidics UK Limited, Burgham Park Residents Association Limited, Zonne Limited and UVCR Limited. Bekanntmachung • Oct 21
Hardide plc Provides Earnings Guidance for the Year Ended September 30, 2024 Hardide plc provided earnings guidance for the year ended September 30, 2024. For the year, the company expects to report revenue of £4.7 million for the year (FY23 £5.5 million). As anticipated, second half ("H2") trading was stronger than the first half ("H1") with H2 sales of £2.6 million, compared with H1 of £2.1 million, despite some delays in new business work now expected in the first half of the new financial year. Board Change • Jul 07
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Andrew Magson was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Bekanntmachung • Jun 18
Steve Paul Steps Down as Director of Hardide plc Hardide plc announced (further to the announcement of 22 May 2024) that Steve Paul, previously interim CEO, has on June 18, 2024, stepped down as a director of the Company following completion of his handover period to Matt Hamblin, ongoing CEO of the Company. Steve will continue to work closely alongside Matt in a sales and business development capacity. Bekanntmachung • May 23
Hardide plc Announces CEO Changes Hardide plc announced that it has appointed Matthew (Matt) Hamblin, currently a non-executive director of the Company, as its new permanent CEO, effective from 3 June 2024. Steve Paul, who is currently serving as interim CEO, will continue to work closely alongside Matt in a sales and business development capacity. Until early 2023 Matt was Chief Executive Officer at Keronite, an advanced coatings and surface treatment company, where he led its growth into profitability and its subsequent sale to the Curtiss-Wright Corporation in November 2022. Matt has prior experience in a variety of sales and commercial leadership roles, including most recently as Commercial Vice President of Nyobolt, a high-performance battery and charging technology company. Bekanntmachung • Feb 22
Hardide plc, Annual General Meeting, Mar 25, 2024 Hardide plc, Annual General Meeting, Mar 25, 2024, at 11:30 Coordinated Universal Time. Location: the offices of Hardide plc, 9 Longlands Road, Bicester, Oxfordshire OX26 5AH Oxfordshire United Kingdom New Risk • Feb 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£3.68m market cap, or US$4.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£900k net loss next year). Share price has been volatile over the past 3 months (7.8% average weekly change). Reported Earnings • Feb 08
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: UK£0.019 loss per share (improved from UK£0.039 loss in FY 2022). Revenue: UK£5.50m (up 9.7% from FY 2022). Net loss: UK£1.12m (loss narrowed 49% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.0%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Bekanntmachung • Feb 08
Hardide plc Appoints Stephen Paul as Interim Chief Executive Officer, Effective 12 February 2024 Hardide plc announced the appointment of Stephen (Steve) Paul as Interim Chief Executive Officer with effect from 12 February 2024. Steve will succeed Philip (Phil) Kirkham who, as announced on 1 November 2023, is stepping down after leading the Company for over 11 years. Steve had a successful 30-year international career in various managing director, commercial development and performance improvement roles for the leading global surface treatment business, Praxair Surface Technologies, now part of the Linde Group. Since 2018, Steve has led his own consultancy business, Sketchley GmbH, where he has advised a number of coatings companies, including Hardide, on strategic, business development and operational improvement projects. Steve has a Master's degree in Metallurgical Engineering from the University of Sheffield. Steve has been working with Hardide for a number of months already on the development of sales of coated consumable parts to be supplied direct to end use customers. Steve will serve as CEO and join the Board of Hardide for an interim period of up to six months, after which it is intended he will continue to work with the Group on further international business development opportunities. New Risk • Dec 03
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.48m market cap, or US$8.23m). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£918k net loss next year). Share price has been volatile over the past 3 months (9.6% average weekly change). Bekanntmachung • Oct 18
Hardide plc Provides Earnings Guidance for the Year Ended 30 September 2023 Hardide plc provided earnings guidance for the year ended 30 September 2023. For the year, the company expects to report revenues for 2023 of £5.5 million. New Risk • Oct 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£6.77m market cap, or US$8.21m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£883k net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Reported Earnings • May 18
First half 2023 earnings released First half 2023 results: Revenue: UK£2.89m (up 8.6% from 1H 2022). Net loss: UK£614.0k (loss narrowed 19% from 1H 2022). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 2.2% growth forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Feb 09
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: UK£0.039 loss per share (improved from UK£0.052 loss in FY 2021). Revenue: UK£5.02m (up 39% from FY 2021). Net loss: UK£2.19m (loss narrowed 22% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Bekanntmachung • Jan 25
Hardide plc Announces Resignation of Robert Goddard as Director Hardide plc announced that, as planned, Robert Goddard stepped down from the Board of Directors at close of business on 24 January 2023. Bekanntmachung • Dec 22
Hardide plc to Report Fiscal Year 2022 Results on Feb 08, 2023 Hardide plc announced that they will report fiscal year 2022 results on Feb 08, 2023 Price Target Changed • Nov 16
Price target decreased to UK£0.60 Down from UK£0.80, the current price target is provided by 1 analyst. New target price is 336% above last closing price of UK£0.14. Stock is down 60% over the past year. The company is forecast to post a net loss per share of UK£0.033 next year compared to a net loss per share of UK£0.052 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Senior Independent Non-Executive Director Tim Rice was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • May 10
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up UK£1.43m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Senior Independent Non-Executive Director Tim Rice was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 17
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: UK£0.052 loss per share (down from UK£0.025 loss in FY 2020). Revenue: UK£3.60m (down 24% from FY 2020). Net loss: UK£2.80m (loss widened 117% from FY 2020). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 42% compared to a 3.7% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Reported Earnings • Dec 08
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: UK£0.052 loss per share (down from UK£0.025 loss in FY 2020). Revenue: UK£3.60m (down 24% from FY 2020). Net loss: UK£2.80m (loss widened 117% from FY 2020). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) exceeded analyst estimates by 11%. Earnings per share (EPS) surpassed analyst estimates by 11%. Over the next year, revenue is forecast to grow 42% compared to a 1.0% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 21
Full year 2020 earnings released: UK£0.025 loss per share (vs UK£0.025 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: UK£4.76m (down 5.9% from FY 2019). Net loss: UK£1.29m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Feb 21
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is expected to shrink by 15% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Bekanntmachung • Feb 20
Hardide plc, Annual General Meeting, Mar 15, 2021 Hardide plc, Annual General Meeting, Mar 15, 2021, at 11:30 Coordinated Universal Time. Location: Offices of the Company at 9 Longlands Road Bicester Oxfordshire United Kingdom Agenda: To consider the financial statements of the company for the financial year ended 30 September 2020 and the reports of the directors and auditor thereon; to consider Mr. Andrew Boyce, who retires by rotation under the articles of association of the company, be re-elected as a director of the company; to consider Mr. Simon Hallam, who was appointed since the last Annual General Meeting, be elected as a director of the company; to consider James Cowper Kreston be re-appointed as auditor of the Company; to consider the directors be authorized to determine the auditor's remuneration; and to consider other matters. Is New 90 Day High Low • Feb 16
New 90-day low: UK£0.29 The company is down 3.0% from its price of UK£0.30 on 18 November 2020. The British market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. Bekanntmachung • Feb 02
Hardide plc has completed a Follow-on Equity Offering in the amount of £0.791 million. Hardide plc has completed a Follow-on Equity Offering in the amount of £0.791 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,559,872
Price\Range: £0.309
Transaction Features: Subsequent Direct Listing Analyst Estimate Surprise Post Earnings • Dec 08
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is forecast to grow 25% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Dec 07
Full year 2020 earnings released: UK£0.025 loss per share The company reported a poor full year result with increased losses and weaker revenues and control over expenses. Full year 2020 results: Revenue: UK£4.76m (down 5.9% from FY 2019). Net loss: UK£1.29m (loss widened 14% from FY 2019). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 20
New 90-day high: UK£0.35 The company is up 43% from its price of UK£0.24 on 21 August 2020. The British market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Bekanntmachung • Sep 23
Hardide plc to Report Fiscal Year 2020 Results on Dec 07, 2020 Hardide plc announced that they will report fiscal year 2020 results on Dec 07, 2020 Is New 90 Day High Low • Sep 22
New 90-day low: UK£0.21 The company is down 46% from its price of UK£0.40 on 24 June 2020. The British market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.